Circulating phosphorus level and risk of prostate cancer: a Mendelian randomization study

2021 ◽  
Author(s):  
Linshuoshuo Lv ◽  
Ding Ye ◽  
Jie Chen ◽  
Yu Qian ◽  
Alan Nuo Fu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Observational Studies ◽  
Mendelian Randomization ◽  
Meta Analysis ◽  
Serum Phosphorus ◽  
Phosphorus Level ◽  
Dietary Phosphorus ◽  
Dietary Phosphorus Intake ◽  
Phosphorus Intake ◽  
Phosphorus Levels

Abstract Background Recent observational studies have suggested that circulating phosphorus levels are positively associated with risk of prostate cancer. However, little is known about the causal direction of the association. Objective To explore the potential causal relationship between circulating phosphorus and risk of prostate cancer, we conducted a Mendelian randomization (MR) study. Design Summary statistics of prostate cancer were obtained from a meta-analysis of genome-wide association studies (GWAS) consisting of 79,148 cases and 61,106 controls. Single nucleotide polymorphisms (SNP) associated with serum phosphorus level were selected from a GWAS of 291,408 individuals from the UK Biobank. MR analysis was performed using the inverse-variance weighted (IVW) method, supplemented with simple-median, weighted-median, maximum likelihood-based, MR-Egger regression and MR-PRESSO test. We also performed a meta-analysis of observational studies to assess the associations of dietary phosphorus intake and serum phosphorus level with risk of prostate cancer. Results In the MR analysis, a total of 125 independent SNPs associated with serum phosphorus levels were used as instrumental variables. Genetically predicted serum phosphorus levels were associated with a 19% increased risk of prostate cancer (95% confidence interval (CI): 9%, 31%) per one SD increment of serum phosphorus by IVW (P = 1.82 × 10–4). Sensitivity analyses using alternative MR methods produced similar positive associations, and no evidence of pleiotropy was detected by MR-Egger regression (P = 0.422). For meta-analysis, eight studies for dietary phosphorus intake and four for serum phosphorus levels were included involving a total of 669,080 participants. Consistently, high dietary phosphorus intake and serum phosphorus levels were associated with an 8% (95% CI: 4%, 12%) and 7% (95% CI: 1%, 14%) increase in prostate cancer risk, respectively. Conclusions Our study suggested a potential causal relationship between circulating phosphorus and risk of prostate cancer. Further studies are warranted to elucidate the underlying mechanism of phosphorus in the development of prostate cancer.

scholarly journals Assessing Dietary Phosphorus Intake and Serum Phosphorus in Adults with Liver Conditions: NHANES 2015–2016

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 341-341
Author(s):  
Sowmiya Muthuraju ◽  
Derek Miketinas
Keyword(s):  
Liver Cancer ◽  
Cross Sectional Study ◽  
Serum Phosphorus ◽  
Cross Sectional ◽  
Funding Sources ◽  
Dietary Phosphorus ◽  
Usual Intake ◽  
Low Phosphorus ◽  
Phosphorus Intake ◽  
Phosphorus Levels

Abstract Objectives Patients with liver conditions may have increased phosphorus turnover which can increase the risk of severe hypophosphatemia and other complications. The objective of this cross-sectional study was to quantify the usual intake of phosphorus, assess serum phosphorus (SP) levels across levels of liver conditions, and to estimate and assess the odds for having critically low phosphorus levels across adults with and without liver conditions. Methods Data were obtained from the NHANES 2015–2016 cycle. Adults were divided into four groups based on self-reported responses from the NHANES medical history questionnaire: liver cancer (LC), unspecified current liver condition (CLC), unspecified resolved liver condition (RLC), and no liver condition. Usual intake was estimated using the NCI method and all analyses were adjusted to account for the complex, multistage, probability sampling design. Results Usual phosphorus intake was highest in participants with RLC (1399 ± 26.5 mg) and lowest in participants with LC (1267 ± 140.7 mg). Although the percentage of those meeting the EAR for phosphorus was high (>95%), SP levels are lowest in participants with LC. SP levels differed slightly across liver conditions: participants with LC had a SP level of 1.0 ± 0.07 mmol/L, while participants with CLC, RLC, or no liver conditions had SP levels of 1.2 ± 0.01 mmol/L, 1.2 ± 0.01 mmol/L, and 1.2 ± 0.02 mmol/L, respectively. Participants with CLC had a usual phosphorus intake of 1350 ± 49.6 mg, and those who had no liver conditions had a usual phosphorus intake of 1387 ± 18.5 mg. The odds for normal phosphorus levels in participants with LC was low (Odds = 0.06; 95% CI: 0.01–0.45); the odds for CLC participants having normal SP levels was 1.6 (95% CI: 1.2–2.15); the odds for normal SP levels in participants with RLC were 2.2 (95% CI: 1.3–3.75), and the odds for normal SP in participants with no liver conditions odds for low were 1.9, (95% CI: 1.71–2.14). Conclusions These results indicate that patients with liver cancer are at higher risk of hypophosphatemia, and that phosphorus recommendations for patients with liver cancer may need to be adjusted. However, the variability in this subpopulation with liver cancer is high and warrants further investigation. Funding Sources None.

Phosphorus turnover in sheep

1967 ◽  
Vol 18 (4) ◽  
pp. 635 ◽  
Author(s):  
FM Tomas ◽  
RJ Moir ◽  
M Somers
Keyword(s):  
Rumen Fluid ◽  
Inorganic Phosphorus ◽  
Dietary Phosphorus ◽  
The Mean ◽  
Four Levels ◽  
Dietary Phosphorus Intake ◽  
Phosphorus Turnover ◽  
Very High ◽  
Phosphorus Intake ◽  
Phosphorus Levels

Rumen fluid, serum, and parotid salivary inorganic phosphorus concentrations in sheep given four levels of dietary phosphorus (0.42–4.02 g/day) were directly related to phosphorus intake. There was a very high correlation (r = +0.91; P < 0.001) between inorganic phosphorus concentrations in centrifuged rumen fluid and in parotid saliva. Serum inorganic phosphorus concentrations were positively correlated with those of saliva (r = +0.64; P< 0.05) and also with those in centrifuged rumen fluid (r = +0.75; P<0.01). The range in the mean daily saliva volumes collected from one parotid gland in each sheep was 3.2 to 4.2 l/day. The calculated minimum total salivary phosphorus secretion ranged from 3.0 g/day on the lowest dietary phosphorus intake to 5.3 g/day on the highest, the corresponding ratios of salivary to dietary phosphorus being from 7.24 to 1 .32 g/g. It appeared that salivary phosphorus was the major source of phosphorus to the rumen, and was also the principal determinant of rumen fluid inorganic phosphorus levels.

scholarly journals Fluctuating plasma phosphorus level by changes in dietary phosphorus intake induces endothelial dysfunction

2015 ◽  
Vol 56 (1) ◽  
pp. 35-42 ◽  
Author(s):  
Eriko Watari ◽  
Yutaka Taketani ◽  
Tomoyo Kitamura ◽  
Terumi Tanaka ◽  
Hirokazu Ohminami ◽  
...  
Keyword(s):  
Endothelial Dysfunction ◽  
Phosphorus Level ◽  
Dietary Phosphorus ◽  
Dietary Phosphorus Intake ◽  
Phosphorus Intake ◽  
Plasma Phosphorus

scholarly journals Dietary phosphorus intake and blood pressure in adults: a systematic review of randomized trials and prospective observational studies

2019 ◽  
Vol 109 (5) ◽  
pp. 1264-1272 ◽  
Author(s):  
Scott T McClure ◽  
Casey M Rebholz ◽  
Sibyl Medabalimi ◽  
Emily A Hu ◽  
Zhe Xu ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Observational Studies ◽  
Randomized Trials ◽  
Intervention Studies ◽  
The United States ◽  
Inverse Association ◽  
Significant Inverse Association ◽  
Dietary Phosphorus ◽  
Dietary Phosphorus Intake ◽  
Phosphorus Intake

ABSTRACT Background Elevated blood pressure (BP) is a major cause of preventable disease in the United States and around the world. It has been postulated that phosphorus intake may affect BP, with some studies suggesting a direct and others an inverse association. Objectives We systematically reviewed the literature on the association of dietary phosphorus with BP in adults and performed a qualitative synthesis. Methods We included randomized and nonrandomized behavioral intervention and feeding studies (intervention studies) and prospective observational studies that measured dietary phosphorus intake or urinary phosphorus excretion and BP. We excluded studies of supplements, children, or individuals with major medical conditions. We searched PubMed, Embase, Cochrane Trials, and clinicaltrials.gov on 1 June, 2017 and 22 August, 2018. We assessed studies’ risk of bias in their assessment of phosphorus exposure and BP. Results We reviewed 4759 publications and included 14 intervention studies (2497 participants), 3 prospective observational cohorts (17,795 participants), and 2 ongoing trials. No included intervention studies were designed specifically to achieve a phosphorus contrast. Two studies found a significant positive association of dietary phosphorus with systolic BP, 4 a significant inverse association, and 8 no significant association. Four studies found a significant inverse association with diastolic BP and 10 no significant associations. Two cohorts found lower risk of incident hypertension comparing the highest with the lowest quintiles of phosphorus intake and 1 found no significant difference: HR: 0.86 (95% CI: 0.75, 0.98); HR: 0.83 (95% CI: 0.68, 1.02); and HR: 0.75 (95% CI: 0.45, 1.27), respectively. Conclusions We found no consistent association between total dietary phosphorus intake and BP in adults in the published literature nor any randomized trials designed to examine this association. This trial was registered at www.crd.york.ac.uk/prospero/ as CRD42017062489.

MO593CONTROLLING DIETARY PHOSPHORUS IN CHRONIC KIDNEY DISEASE STAGES 1 AND 2  DECREASES PROTEINURIA AND PREVENTS DECLINE IN RENAL FUNCTION

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Anita Saxena ◽  
Amit Gupta ◽  
Trisha Sachan ◽  
Vishwas Kapoor ◽  
Anup Kumar ◽  
...  
Keyword(s):  
Dietary Protein ◽  
Serum Phosphorus ◽  
Dietary Phosphorus ◽  
Significant Difference ◽  
Low Phosphorus ◽  
Group 2 ◽  
Dietary Phosphorus Intake ◽  
Fgf 23 ◽  
Phosphorus Intake ◽  
Group 1

Abstract Background and Aims High phosphorus intake is known to cause renal and vascular calcification and renal tubular injury and albuminuria. Dietary phosphorus restriction is therapeutic for controlling disordered phosphorus homeostasis and for improving cardiovascular outcomes in CKD. However, early restriction of dietary phosphorus is not advocated Aim: To evaluate if early control of dietary phosphorus ameliorates proteinuria, prevents decline in glomerular filtration rate and prevents increase in FGF-23 Method One year longitudinal study on 79 CKD patients in stages 1 and 2. eGFR, serum creatinine , phosphorus, calcium, FGF-23, soluble α-Klotho iPTH FGF 23, blood pressure, were evaluated and compared with 35 controls. 3 days dietary intake was taken using standard methodology on first visit, 6 and 12 months. CKD patients were grouped based on dietary phosphorus intake: Group 1 (n 42): normal phosphorous intake (&lt;1000mg/day) and Group 2 (n=37; 17 in CKD 1; 20 CKD 2): high phosphorous intake (&gt;1000mg/d). Patients in Group 2 were educated on high and low phosphorus foods and counselled to avoid fresh and frozen and processed meat, eggs, nuts and seeds, chocolates, packaged food, phosphorus-containing food additives and counselled to adopt a plant-based diet, for low phosphorus availability/absorption diet with directed diet plan. Lentils and pulses, milk and milk products (hard cheese, ice-creams, custards, cottage cheese, pudding, yoghurt), bran and whole wheat cereals were restricted up to 1-2 servings a day Data were analysed using SPSS. Results At baseline there was no significant difference in the GFR (group1 85.00±18.64 ml/min vs group 2 82.53±16.30ml/min), serum creatinine between groups. In group2 ; GFR, sKlotho, serum phosphorus and FGF-23 correlated significantly with dietary phosphorus intake. In group 2, FGF-23, Serum phosphorus, dietary protein and phosphorus intake were significantly higher and sKlotho was significantly lower than group 1. There was significant difference in serum phosphorus (p 0.000), iPTH, (p 0.004), FGF23 (p0.000), Klotho (p0.000), urinary protein (p0.000), dietary protein (Group 1 37.57±3.40; Group 248.79±5.86 p 0.000) and phosphorus (Group 1868.96±69.99 mg/d and Group 2 1312.26±137.57 mg/d p 0.000) intake and dietary phosphorous to protein ratio (p 0.000) between groups 1 and 2.. After dietary intervention in group 2 GFR increased from 80.93±15.34 to 84.11±15.38 in six months and to 87.43±18.27 ml/min at 12 months p 0.012, and urinary protein declined to 22.01±3.39 mg/mL. FGF 23 declined from 60.67±6.26 to 58.00±7.07 to 53.29±9.48 pg/mL at 12 months. Urinary phosphorus excretion increased from 574.37±214.22 to 624.64±137.67 at 12 months. Dietary phosphorus protein to ratio reduced from 27.16±4.35 to24.75±4.34 p 0.000 at 12 months Conclusion CKD patients should be cautioned and counselled on their first visit on the impact of dietary phosphorus intake on the progression of CKD and development of CVD.

MO582LONGITUDINAL STUDY TO FIND THE ASSOCIATION OF SERUM PHOSPHORUS LEVEL WITH FGF 23 IN THREE DIFFERENT HYPERPHOSPHATEMIA MANAGEMENTS GROUPS OF STAGE 3 AND 4 CHRONIC KIDNEY DISEASE (CKD) PATIENTS

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Navjot Kaur ◽  
Himansu Mahapatra ◽  
Neera Sharma ◽  
Lalit Pursnani ◽  
Muthukumar B ◽  
...  
Keyword(s):  
Dietary Assessment ◽  
Serum Phosphorus ◽  
Phosphorus Level ◽  
Treatment Groups ◽  
Dietary Phosphorus ◽  
2D Echocardiography ◽  
Significant Difference ◽  
One Year ◽  
Fgf 23 ◽  
Phosphorus Levels

Abstract Background and Aims There were paucity of clinical evidence on target serum phosphorus levelsin early CKD. Present longitudinal study finds target phosphorus level and its association with FGF 23 in three different hyperphosphatemia managements groups. Method This one year, prospective, randomised controlled, open labelled study was conducted among three equally allocated treatment groups in 120 screened early CKD patients.Group1 Dietary phosphorus modificationn40; Group2 calcium-based phosphate bindersn40 and Group3 non calcium-based phosphate bindersn40.Three monthly dietary assessment, MDRD e-GFR, phosphorus, calcium, iPTH, Alkaline phosphatise and six monthly FGF23, 2D Echocardiography, X ray of chest and abdomen were performed. Association of three categories of phosphorus level up to 3.9 mg/dl, 4 to 5mg/dl and &gt;5mg/dl, rate of progression of all parameters and correlation with FGF 23among all three groups were studied. Results At baseline, all clinical and biochemical parameters were equally distributed with a controlled nutritional phosphate among all groups. There was no significant difference of FGF23 in all the three categories of phosphorus level among all groups. Association of serum phosphorus at the level of 5 mg/dl was there with iPTH and e-GFR at one year. Over one year there were significant decline in serum phosphorus levels in Group1 p 0.02, Group2 p 0.00,Group3p 0.05;FGF23 was declined significantly only in group3p 0.00.Correlation of FGF23 was positive and negative with iPTH r 0.19,p 0.03 and e-GFR r-0.30, p 0.00respectively but not with phosphorus p0.13 Conclusion Serum phosphorus levels up to 5mg/dl has no effect on FGF 23 at early CKD stages. Although different treatment groups have significant phosphorus reduction, non-calcium phosphate binder has major impact on FGF23 reduction.

scholarly journals High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III

2013 ◽  
Vol 99 (2) ◽  
pp. 320-327 ◽  
Author(s):  
Alex R Chang ◽  
Mariana Lazo ◽  
Lawrence J Appel ◽  
Orlando M Gutiérrez ◽  
Morgan E Grams
Keyword(s):  
Nhanes Iii ◽  
Dietary Phosphorus ◽  
All Cause Mortality ◽  
Dietary Phosphorus Intake ◽  
Phosphorus Intake
Sign in / Sign up

Export Citation Format

Share Document